TREA

79169309 - ADLIB

Follow

Information

  • Trademark
  • 79169309
  • Serial Number
    79169309
  • Registration Number
    5139363
  • Filing Date
    April 28, 2015
    9 years ago
  • Registration Date
    February 14, 2017
    7 years ago
  • Transaction Date
    May 10, 2024
    7 months ago
  • Status Date
    June 10, 2023
    a year ago
  • Published for Opposition Date
    November 29, 2016
    8 years ago
  • Location Date
    June 10, 2023
    a year ago
  • Status Code
    707
  • Employee Name
    MAHONEY, PAULA M
  • Attorney Docket Number
    T66873
    Attorney Name
    Jeffrey H. Handelsman
    Law Office Assigned Location Code
    N10
  • Owners
Information
Mark Drawing Code
4
Mark Identification
ADLIB
Case File Statements
  • B00001: In the statement, "the entire class 042" should be deleted, and Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals should be inserted.
  • GS0051: [ Monoclonal antibodies for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; peptides and proteins for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; biological and chemical preparations and reagents for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for human purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for dental purposes, namely, for infectious diseases, neurological diseases or inflammatory diseases; medicines for veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicinal preparations, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposes, namely, for cultivating living cells or cell lines used for manufacturing monoclonal antibodies; surgical implants comprised of living tissues; biological implants, namely, a vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin ]
  • GS0421: [ Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ] * Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; ] research and development in the field of biotechnology; pharmaceutical research and development; [ conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; ] technical project studies in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; research and development of new products for others [ ; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals * ]
Case File Event Statements
  • 7/29/2015 - 9 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 7/23/2015 - 9 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 7/25/2015 - 9 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 2/15/2016 - 8 years ago
    13 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 8/8/2015 - 9 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 8/13/2015 - 9 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 8/14/2015 - 9 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 8/14/2015 - 9 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 8/14/2015 - 9 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 9/4/2015 - 9 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 2/15/2016 - 8 years ago
    10 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 2/15/2016 - 8 years ago
    11 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 2/15/2016 - 8 years ago
    12 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 2/16/2016 - 8 years ago
    14 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 10/13/2016 - 8 years ago
    23 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 3/10/2016 - 8 years ago
    15 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 3/10/2016 - 8 years ago
    16 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 3/10/2016 - 8 years ago
    17 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 9/15/2016 - 8 years ago
    18 - ASSIGNED TO LIE Type: ALIE
  • 9/19/2016 - 8 years ago
    19 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK
  • 9/23/2016 - 8 years ago
    20 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 9/23/2016 - 8 years ago
    21 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 9/24/2016 - 8 years ago
    22 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 10/27/2016 - 8 years ago
    24 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV
  • 11/9/2016 - 8 years ago
    27 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 12/28/2016 - 8 years ago
    33 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 11/9/2016 - 8 years ago
    25 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 11/9/2016 - 8 years ago
    26 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 11/29/2016 - 8 years ago
    28 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 11/29/2016 - 8 years ago
    29 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 12/16/2016 - 8 years ago
    30 - TEAS POST PUBLICATION AMENDMENT RECEIVED Type: EPPA
  • 12/16/2016 - 8 years ago
    31 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 12/28/2016 - 8 years ago
    32 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 6/6/2017 - 7 years ago
    39 - ASSIGNED TO PARALEGAL Type: PLGL
  • 6/23/2017 - 7 years ago
    40 - CORRECTION UNDER SECTION 7 - PROCESSED Type: COC.
  • 9/15/2017 - 7 years ago
    43 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 1/31/2017 - 7 years ago
    34 - ASSIGNED TO PETITION STAFF Type: APET
  • 2/1/2017 - 7 years ago
    35 - APPLICANT SUPPLIED CHANGES/CORRECTIONS AFTER PUB APPROVAL NOT ENT Type: CHPN
  • 2/14/2017 - 7 years ago
    36 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 3/9/2017 - 7 years ago
    37 - TEAS SECTION 7 REQUEST RECEIVED Type: ES7R
  • 5/14/2017 - 7 years ago
    38 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 8/4/2017 - 7 years ago
    41 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 9/15/2017 - 7 years ago
    42 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 2/14/2022 - 2 years ago
    47 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3
  • 11/15/2022 - 2 years ago
    48 - TEAS SECTION 71 RECEIVED Type: ES71
  • 10/28/2017 - 7 years ago
    44 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 2/23/2018 - 6 years ago
    45 - PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED Type: INPR
  • 3/7/2018 - 6 years ago
    46 - INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE Type: INNA
  • 5/29/2023 - a year ago
    49 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE
  • 6/10/2023 - a year ago
    50 - REGISTERED - PARTIAL SEC 71 ACCEPTED Type: 71.P
  • 6/10/2023 - a year ago
    51 - NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED Type: NA71
  • 2/10/2024 - 10 months ago
    52 - PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED Type: INPR
  • 2/26/2024 - 10 months ago
    54 - PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB Type: INPS
  • 2/26/2024 - 10 months ago
    53 - INVALIDATION PROCESSED Type: INPC
  • 4/1/2024 - 9 months ago
    55 - PARTIAL INVALIDATION PROCESSED BY THE IB Type: INNP